Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study

Published:2019-12-28 Issue:12 Volume:146 Page:3504-3515
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Urakawa Hiroshi¹²^ORCID,Ando Yuichi²,Hase Tetsunari³,Kikumori Toyone⁴,Arai Eisuke¹,Maeda Osamu²,Mitsuma Ayako²,Sugishita Mihoko²,Shimokata Tomoya²,Ikuta Kunihiro¹,Ishiguro Naoki¹,Nishida Yoshihiro¹⁵

Affiliation:

1. Department of Orthopaedic Surgery Nagoya University Nagoya Japan

2. Department of Clinical Oncology and Chemotherapy Nagoya University Hospital Nagoya Japan

3. Department of Respiratory Medicine Nagoya University Hospital Nagoya Japan

4. Department of Breast and Endocrine Surgery Nagoya University Graduate School and School of Medicine Nagoya Japan

5. Department of Rehabilitation Nagoya University Hospital Nagoya Japan

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32836

Reference34 articles.

1. Zoledronic Acid Significantly Reduces Skeletal Complications Compared With Placebo in Japanese Women With Bone Metastases From Breast Cancer: A Randomized, Placebo-Controlled Trial

2. Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer

3. Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

4. Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

5. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of the efficacy and safety of a proposed biosimilar QL1206 with reference denosumab in patients with bone metastasis from breast cancer: a subgroup analysis of a randomized, double-blinded phase III study;2024-06-11

2. Assessment of bone turnover markers and DXA parameters to predict bone metastasis progression during zoledronate treatment: a single-center experience;Clinical and Experimental Medicine;2024-01-19

3. CT-guided percutaneous microwave ablation combined with bone cement injection for the treatment of transverse metastases: A case report;Open Medicine;2023-01-01

4. A clinical trial of a unidirectional porous tricalcium phosphate filling for defects after resection of benign bone lesions: a prospective multicenter study;Scientific Reports;2022-09-26

5. Analysis of the Mechanism and Safety of Bisphosphonates in Patients with Lung Cancer and Bone Metastases;Computational and Mathematical Methods in Medicine;2021-12-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3